Tempest Therapeutics

TPST

Biotechnology · Healthcare

Price

$1.21

+0.03 (+2.54%)

Market Cap

$19.3M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1323.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 292K (2021) → 4.1M (2025)

Tempest Therapeutics is a small clinical-stage biotech company that is trying to develop new drugs to treat cancer. It does not sell any products yet — instead, it runs clinical trials testing experimental medicines on cancer patients. The company focuses on compounds that target the tumor microenvironment, meaning they try to change the conditions around a tumor to help the immune system fight it better.

Tempest makes no revenue from product sales right now. It funds its research through cash on hand, equity offerings, and any partnership deals it can secure with larger pharmaceutical companies. The company operates primarily in the United States and, like most clinical-stage biotechs, has a very small team and burns through cash each quarter. The biggest risk it faces is that its drug candidates could fail in clinical trials, which would likely force it to raise more money by selling new shares and diluting existing investors.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+19.9% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$13M/ year

↓ Declining (-56% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

6.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

$2M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Tempest Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-372.7%

Weak — -372.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

8.05

Heavy debt load (8.05)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial